Description
Distinguished scientists and members of the medical profession discuss the research and development of safe and suitable drugs for the long-term treatment of chronic diseases. The book provides an up-to-date survey on new insights and technologies – as well as ethical considerations – , since traditional means and methods of drug research and drug development may no longer suffice to meet the challenges of the next century. History and Philosophy of Bayer Pharmaceutical Research.- Science, Responsibility, and Society.- Opening Remarks.- Message of Greeting.- I. Unresolved Problems of Chronic Diseases.- Demographic and Epidemiologic Trends Today.- Discussion.- Atherosclerosis and Coronary Heart Disease.- Discussion.- Rheumatoid Arthritis: A Modell of Chronic Inflammation.- Discussion.- Alzheimer’s Disease.- Discussion.- Obstructive Lung Disease.- Discussion.- Biological Approaches to Cancer Therapy.- Discussion.- Challenges and Obstacles hi Clinical Evaluations of Therapy.- Problems, Pitfalls, and Opportunities in Long-term Randomized Trials.- Discussion.- The Impact of Clinical Trials on Clinical Practice.- Discussion.- Panel Discussion I: Cost Effectiveness of Drug Development and Health Economics.- II. Advanced Technologies, Scientific Achievements.- Receptors and Messengers.- Low Density Lipoproteins and Hypercholesterolemia.- Discussion.- Leukotrienes in Airways and Blood Vessels.- Discussion.- Drug Design.- Opening Remarks.- Thoughts About Gene Regulation and Mammalian Development.- Discussion.- Protein Crystallography and Drug Design.- Discussion.- Applying Engineering Principles to the Design of Cellular Biology.- Discussion.- Analytical Pathophysiology and Biochemistry.- Opening Remarks.- Neurotransmitters in the Brain.- Discussion.- Mechanisms of Cancer Metastasis.- Discussion.- Panel Discussion II: Objectives of Basic Research and Predictive Value Preclinical Testing.- The Patient as a Subject to Medical Research.- Ethics of Drug Research and Drug Development.- Discussion.- The Functions of Ethical Committees.- Discussion.- Reduction of Risk to Patients Through Optimized Planning of Clinical Drug Development.- Discussion.- The Quality of Life of Hypertensive Patients in Long-term Studies.- Discussion.- Panel Discussion III: Who is Concerned with Patient Welfare in Research?.- Concluding Remarks.
